La Jolla Pharmaceutical (LJPC) Short Interest Ratio & Short Volume

Short interest is the volume of La Jolla Pharmaceutical shares that have been sold short but have not yet been covered or closed out. As of July 31st, traders have sold 95,700 shares of LJPC short. 0.38% of La Jolla Pharmaceutical's shares are currently sold short. Learn More on La Jolla Pharmaceutical's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.38% of La Jolla Pharmaceutical's floating shares are currently sold short.

La Jolla Pharmaceutical saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 95,700 shares, a drop of 52.7% from the previous total of 202,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

La Jolla Pharmaceutical currently has issued a total of 24,937,000 shares. Some of La Jolla Pharmaceutical's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. La Jolla Pharmaceutical currently has a public float of 25,070,000 shares.

0.38% of La Jolla Pharmaceutical's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to La Jolla Pharmaceutical: Autolus Therapeutics plc (5.85%), Relay Therapeutics, Inc. (14.14%), Taysha Gene Therapies, Inc. (16.04%), MeiraGTx Holdings plc (4.37%), Cullinan Therapeutics, Inc. (17.20%), Opthea Limited (0.36%), Valneva SE (0.00%), Atyr PHARMA INC (16.00%), REGENXBIO Inc. (13.99%), Tourmaline Bio, Inc. (18.81%),

As of the most recent reporting period, the following stocks had the largest short interest positions: KLA Co. ($2.87 billion), Lucid Group, Inc. ($2.25 billion), T. Rowe Price Group, Inc. ($2.08 billion), Coinbase Global, Inc. ($1.91 billion), Williams-Sonoma, Inc. ($1.85 billion), Chesapeake Energy Co. ($1.81 billion), Rivian Automotive, Inc. ($1.64 billion), Lumen Technologies, Inc. ($1.61 billion), Plug Power Inc. ($1.50 billion), and Generac Holdings Inc. ($1.49 billion). View all of the most shorted stocks.

Short selling LJPC is an investing strategy that aims to generate trading profit from La Jolla Pharmaceutical as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for La Jolla Pharmaceutical occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LJPC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LJPC, twice per month. The most recent reporting period available is July, 31 2022.